image
Healthcare - Biotechnology - NASDAQ - US
$ 5.8
2 %
$ 795 M
Market Cap
-1.46
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one VIR stock under the worst case scenario is HIDDEN Compared to the current market price of 5.8 USD, Vir Biotechnology, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one VIR stock under the base case scenario is HIDDEN Compared to the current market price of 5.8 USD, Vir Biotechnology, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one VIR stock under the best case scenario is HIDDEN Compared to the current market price of 5.8 USD, Vir Biotechnology, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart VIR

image
$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
74.2 M REVENUE
-13.90%
-587 M OPERATING INCOME
14.20%
-522 M NET INCOME
15.14%
-446 M OPERATING CASH FLOW
42.69%
499 M INVESTING CASH FLOW
203.33%
4.39 M FINANCING CASH FLOW
-41.34%
11.3 M REVENUE
373.87%
-117 M OPERATING INCOME
46.41%
-105 M NET INCOME
51.06%
-87.6 M OPERATING CASH FLOW
48.89%
141 M INVESTING CASH FLOW
18.66%
1.26 M FINANCING CASH FLOW
3974.19%
Balance Sheet Vir Biotechnology, Inc.
image
Current Assets 1.04 B
Cash & Short-Term Investments 990 M
Receivables 0
Other Current Assets 52.1 M
Non-Current Assets 356 M
Long-Term Investments 190 M
PP&E 123 M
Other Non-Current Assets 43.5 M
70.80 %3.72 %13.58 %8.78 %3.11 %Total Assets$1.4b
Current Liabilities 120 M
Accounts Payable 5.08 M
Short-Term Debt 0
Other Current Liabilities 115 M
Non-Current Liabilities 129 M
Long-Term Debt 90.1 M
Other Non-Current Liabilities 38.6 M
46.12 %36.28 %15.55 %Total Liabilities$248.4m
EFFICIENCY
Earnings Waterfall Vir Biotechnology, Inc.
image
Revenue 74.2 M
Cost Of Revenue 845 K
Gross Profit 73.4 M
Operating Expenses 661 M
Operating Income -587 M
Other Expenses -65.2 M
Net Income -522 M
100m100m00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)(500m)(500m)(600m)(600m)74m(845k)73m(661m)(587m)65m(522m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
98.86% GROSS MARGIN
98.86%
-791.27% OPERATING MARGIN
-791.27%
-703.40% NET MARGIN
-703.40%
-45.37% ROE
-45.37%
-37.31% ROA
-37.31%
-45.80% ROIC
-45.80%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Vir Biotechnology, Inc.
image
2b2b2b2b1b1b500m500m00(500m)(500m)(1b)(1b)2018201820192019202020202021202120222022202320232024202420252025
Net Income -522 M
Depreciation & Amortization 20 M
Capital Expenditures -7.3 M
Stock-Based Compensation 78.5 M
Change in Working Capital 0
Others -96.4 M
Free Cash Flow -454 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Vir Biotechnology, Inc.
image
Wall Street analysts predict an average 1-year price target for VIR of $22.5 , with forecasts ranging from a low of $15 to a high of $28 .
VIR Lowest Price Target Wall Street Target
15 USD 158.62%
VIR Average Price Target Wall Street Target
22.5 USD 287.93%
VIR Highest Price Target Wall Street Target
28 USD 382.76%
Price
Max Price Target
Min Price Target
Average Price Target
3030252520201515101055Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Vir Biotechnology, Inc.
image
Sold
0-3 MONTHS
1.11 M USD 5
3-6 MONTHS
215 K USD 2
6-9 MONTHS
95 K USD 1
9-12 MONTHS
43.8 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure Data from Multiple Ongoing Late-Stage Studies Reinforce Brii Bio's HBV Functional Cure Strategy of Optimized Combination Regimens to Target Patient Populations 4 Abstracts Including 2 Oral Presentations with Data from the Ongoing Phase 2 ENSURE Study at the Upcoming APASL (March 26-30) Strong Cash Reserves of US$335.7 Million to Propel Operations into 2028 Actively Seeking Partnership Opportunities for Non-HBV Programs Conference Call (English Session) Scheduled for March 31 at 8:30 PM HKT / 8:30 AM ET DURHAM, N.C. and BEIJING, China , March 21, 2025 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health across diseases with high unmet medical needs provided a corporate update today and reported its financial results for the year ended December 31, 2024. prnewswire.com - 1 month ago
Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript Vir Biotechnology, Inc. (NASDAQ:VIR ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief Executive Officer Mark Eisner - Executive Vice President & Chief Medical Officer Jason O'Byrne - Executive Vice President & Chief Financial Officer Mika Derynck - Executive Vice President of Therapeutic Head Oncology Conference Call Participants Hang Hu - Barclays Paul Choi - Goldman Sachs Phil Nadeau - TD Cowen Alec Stranahan - Bank of America Joseph Stringer - Needham Patrick Trucchio - H.C. Wainwright & Co. Operator Hello. seekingalpha.com - 2 months ago
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.86 per share a year ago. zacks.com - 2 months ago
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2024. “2024 was a year of transformation for Vir Biotechnology as we successfully defined and executed on our renewed strategic direction, focusing our resources on our most promising programs in infectious diseases and oncology,” said Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, Vir Bio. businesswire.com - 2 months ago
Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the executive team are scheduled to participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4 at 8:50 a.m. PT / 11:50 a.m. ET in Boston, Massachusetts. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days. About Vir Biotech. businesswire.com - 2 months ago
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025 This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions. seekingalpha.com - 3 months ago
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why On Wednesday, Vir Biotechnology, Inc.  VIR presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid tumors, and VIR-5500, which targets PSMA in metastatic castration-resistant prostate cancer (mCRPC). benzinga.com - 3 months ago
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates Vir Biotechnology posts encouraging initial data from phase I studies evaluating VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors. zacks.com - 3 months ago
Vir Biotechnology: A Rocket Off Phase 1 Data Vir Biotechnology's recent share price rally is driven by their promising cancer program, despite their primary focus on hepatitis management. The company's market cap has surged past $1 billion, raising questions about the sustainability and justification of this valuation. The early data for their T cell engagers suggest favorable safety, with hints of efficacy and a boatload more patients in phase 1 waiting for more evaluation. seekingalpha.com - 3 months ago
Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why On Wednesday, Vir Biotechnology, Inc.  VIR stock traded higher after the company presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid tumors, and VIR-5500, which targets PSMA in metastatic castration-resistant prostate cancer (mCRPC). benzinga.com - 3 months ago
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today is presenting initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, targeting a variety of HER2-expressing solid tumors; and VIR-5500, targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC). Data show encouraging preliminary safety and efficacy profiles with no dose-limiting cytokine release syndrome (CRS), maximum tolerated dose (MTD) not yet reached as dose escalation co. businesswire.com - 3 months ago
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, at 4:30 p.m. PT in San Francisco, California. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website at www.vir.bio and will be archived there for 30 days. About. businesswire.com - 4 months ago
8. Profile Summary

Vir Biotechnology, Inc. VIR

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 795 M
Dividend Yield 0.00%
Description Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Contact 499 Illinois Street, San Francisco, CA, 94158 https://www.vir.bio
IPO Date Oct. 11, 2019
Employees 408
Officers Dr. Mark D. Eisner M.D., M.P.H. Executive Vice President & Chief Medical Officer Dr. Jennifer Eileen Towne Ph.D. Executive Vice President & Chief Scientific Officer Dr. Maninder Hora Ph.D. Executive Vice President & Chief Technical Operations Officer Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. Chief Executive Officer & Director Dr. Lawrence Corey M.D. Co-Founder & Scientific Advisor Dr. Louis J. Picker M.D. Co-Founder & Scientific Advisor Mr. Jason O'Byrne M.B.A. Executive Vice President & Chief Financial Officer Ms. Vanina de Verneuil J.D. Executive Vice President, General Counsel & Corporate Secretary Mr. Toby Medaris Senior Vice President of Human Resources Mr. Brent Sabatini Senior Vice President, Principal Accounting Officer & Chief Accounting Officer